ReviewLancet (London, England)2021
Histiocytosis.
Review in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 116 citations in OpenAlex.
- Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.Blood advances · 2026Trial
- True brachial artery aneurysm secondary to arterial wall infiltration by Langerhans cell histiocytosis.Journal of vascular surgery cases and innovative techniques · 2026Article
- Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.European journal of haematology · 2026Article
- Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.Blood advances · 2026Article
- Article
- Glomeruloid haemangioma in Erdheim-Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor-A levels.British journal of haematology · 2026Article
- Clinical utility of copeptin in histiocytosis-associated arginine vasopressin deficiency: a report of three cases.Annals of hematology · 2026Article
- Origin, diagnosis and treatment of periocular Histiocytic disorders- state-of-the-art review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.Blood advances · 2026Observational
- A case of mixed histiocytosis (Erdheim-Chester disease and Langerhans cell histiocytosis) with STEAP3-associated anemia and type 4 hemochromatosis.Orphanet journal of rare diseases · 2026Article
- Targeted Therapy in Erdheim-Chester Disease: A Case Report and Review of the Literature.Cureus · 2026Article
- Isolated Esophageal Langerhans Cell Histiocytosis in an Adult: A Case Report.Clinical case reports · 2026Article
- Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.Orphanet journal of rare diseases · 2026Article
- Cutaneous Rosai-Dorfman Disease Misdiagnosed as Granulomatous Dermatitis: A Diagnostic Pitfall.Cureus · 2026Article
- Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts-a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, China.Virchows Archiv : an international journal of pathology · 2026Review
- Rosai-Dorfman disease mimicking testicular malignancy in a patient with marginal zone lymphoma of the lung.BMJ case reports · 2026Article
- Radioresistant but Alectinib-Responsive Isolated Intramedullary ALK-Positive Histiocytosis.Case reports in hematology · 2026Article
- Isolated gastric Langerhans cell histiocytosis: a case report and literature review.Frontiers in oncology · 2026Article
- Tumoral Stage of Mycosis Fungoides, Misdiagnosed With Wells Syndrome and Langerhans Cell Histiocytosis Histologically: A Challenging Case and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- ALK-positive adult histiocytosis with a TFG-ALKfusion gene.The oncologist · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
Abstract
Histiocytoses constitute a heterogeneous group of rare disorders, characterised by infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell phenotypes. Histiocytoses can start at any age. Diagnosis is based on histology in combination with appropriate clinical and radiological findings. The low incidence and broad spectrum of clinical manifestations often leads to diagnostic delay, especially for adults. In most cases, biopsy specimens infiltrated by histiocytes have somatic mutations in genes activating the MAP kinase cell-signalling pathway. These mutations might also be present in blood cells and haematopoietic progenitors of patients with multisystem disease. A comprehensive range of investigations and molecular typing are essential to accurately predict prognosis, which can vary from spontaneous resolution to life-threatening disseminated disease. Targeted therapies with BRAF or MEK inhibitors have revolutionised salvage treatment. However, the type and duration of treatment are still debated, and the prevention of neurological sequelae remains a crucial issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.